Catalog No.
DHC08001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
HLA-DR antigens-associated invariant chain, HLA class II histocompatibility antigen gamma chain, CD74, CLIP, Ia antigen-associated invariant chain, DHLAG, Ii
Concentration
1.77 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04233
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CD74-DOX (ADC), MEDI-115, hLL1, hLL1-DOX (ADC), CAS: 899796-83-9
Clone ID
Milatuzumab
Milatuzumab - a promising new immunotherapeutic agent, PMID: 19968579
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies, PMID: 19053886
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers, PMID: 23427296
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines, PMID: 19351768
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies, PMID: 23209030
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells, PMID: 20574049
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma, PMID: 21228331
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line, PMID: 24386925
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, PMID: 25847298
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression, PMID: 22404985
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas, PMID: 25754579
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab, PMID: 23025988
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma, PMID: 24112026
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?, PMID: 22377620
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death, PMID: 22042694
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates, PMID: 26927803
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach, PMID: 28466956
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE), PMID: 33619162
Emerging antibodies for the treatment of multiple myeloma, PMID: 27195659
Novel targeted therapies for mantle cell lymphoma, PMID: 22361516
Emerging immune targets for the treatment of multiple myeloma, PMID: 29421983
CD74: a new candidate target for the immunotherapy of B-cell neoplasms, PMID: 17875789
The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival, PMID: 21417823
CD84 is a survival receptor for CLL cells, PMID: 23435417
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies, PMID: 24708159
Gateways to clinical trials, PMID: 19455266
CD74 interferes with the expression of fas receptor on the surface of lymphoma cells, PMID: 25304249
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo, PMID: 25937048
CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder, PMID: 22905972
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, PMID: 19223402
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas, PMID: 22271448
The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK), PMID: 27458612
For research use only. Not for human or drug use.
